EDAN(SZ:300206)2024-03-28 16:00Financial Performance - The company's operating revenue for 2023 reached ¥1,937,988,917, representing an increase of 11.22% compared to ¥1,742,412,290 in 2022[32]. - Net profit attributable to shareholders for 2023 was ¥221,301,109, a decrease of 5.00% from ¥232,987,942 in 2022[32]. - The net profit after deducting non-recurring gains and losses was ¥194,472,721, down 3.19% from ¥200,922,822 in the previous year[32]. - The net cash flow from operating activities decreased significantly by 54.96% to ¥150,964,260 from ¥335,157,849 in 2022[32]. - Basic earnings per share for 2023 were ¥0.3818, reflecting a decline of 5.00% compared to ¥0.4020 in 2022[32]. - Total assets at the end of 2023 amounted to ¥2,213,670,947, a slight decrease of 0.98% from ¥2,235,526,840 at the end of 2022[32]. - The net assets attributable to shareholders increased by 6.06% to ¥1,965,276,976 from ¥1,853,056,780 in the previous year[32]. - The company achieved a total revenue of 1,937.99 million yuan in 2023, representing a year-on-year growth of 11.22%[97]. - Domestic market revenue reached 979.26 million yuan, with a year-on-year increase of 15.99%, while international market revenue was 958.73 million yuan, growing by 6.74%[97]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 12%[171]. Product Development and Innovation - The company launched several industry-leading products, including the iX10 Neo neonatal monitor and the AX8 and AX9 ultrasound devices, showcasing its commitment to innovation[6]. - The company is focusing on the development of high-sensitivity magnetic sensors and advanced biochemical target binding methods for its new products[32]. - The company launched the new generation iV series plug-in monitor in 2023, integrating multiple advanced monitoring technologies, enhancing its competitive advantage in the critical care market[58]. - The company has developed the industry-first CNBP continuous non-invasive blood pressure measurement technology, widely accepted by top-tier hospitals[59]. - The company’s blood gas and biochemical analyzers are at the international leading level, contributing to its comprehensive competitive strength in the in vitro diagnostics sector[54]. - The company’s IVD products include high-end microfluidic POCT products, routine testing products, and molecular diagnostic products, with the CL30 fully automated nucleic acid detection analyzer being the first molecular diagnostic product launched[74]. - The i500 fully automated blood gas electrolyte analyzer is expected to be launched in Q1 2024, aiming to disrupt the blood gas market dominated by imported brands[77]. - The company is committed to continuous investment in the IVD field, focusing on product performance enhancement and diversification to strengthen its competitive advantage[81]. - The company launched new blood gas products, which will enhance the variety and total capacity of its product line[125]. - The company is focusing on enhancing its market presence with new product registrations, including a blood oxygen sensor approved on September 17, 2023[163]. Market Expansion and Strategy - The newly established subsidiary in Peru is part of the company's global expansion strategy, with a total of eight overseas subsidiaries now in operation[7]. - The company aims to deepen its localization strategy in international markets and enhance its marketing and sales efforts[7]. - Future outlook includes expanding market presence and enhancing product offerings in the Point of Care Testing (POCT) segment[32]. - The company is expanding its market presence, targeting an increase in sales in Southeast Asia, with a goal of capturing 15% market share by 2025[162]. - The company is actively pursuing regulatory approvals for its new products, ensuring they meet the necessary standards for market entry[166]. - The company is exploring strategic acquisitions to bolster its technology capabilities and market reach[177]. - The company has completed a strategic acquisition of a competitor, which is expected to contribute an additional 300 million RMB in annual revenue[171]. Research and Development - R&D investment for the reporting period was CNY 347.43 million, an increase of 16.77% year-on-year, accounting for 17.93% of total revenue[102]. - The number of R&D personnel increased by 6.19% to 789 in 2023, accounting for 29.28% of the total workforce, up from 27.41% in 2022[146]. - The company has a robust pipeline of medical devices with various registration statuses, indicating a strong commitment to compliance and market readiness[166]. - The company is investing 200 million RMB in R&D for new technologies aimed at improving diagnostic accuracy and efficiency[171]. - The company is focusing on integrating new technologies such as cloud computing, IoT, AI, and 5G to explore new business models in remote and internet healthcare[86]. Awards and Recognition - The company received multiple industry awards, including the title of "Leading Enterprise in High-Quality Development" in 2023[6]. - The company has received multiple accolades for its patents, including being recognized as a national intellectual property advantage enterprise in 2022[102]. - The company has achieved IVDR CE certification for 16 product series and MDR CE certification for 64 product series by the end of 2023, enhancing its market access in Europe[149]. Customer Engagement and Service - The company has established a service network that covers over 50,000 medical institutions in China and has a global presence in over 170 countries and regions[56]. - The company’s after-sales service system has been upgraded to provide 24/7 support across more than 170 countries, ensuring customer satisfaction[107]. - The company achieved a 95% customer satisfaction rate, reflecting strong product performance and service quality[177]. - The company has conducted nearly 800 training sessions through its academic platform, reaching over 220,000 medical professionals and enhancing its brand influence[121].